

Figure S1. Patient repartition according to the age (< or ≥ 70 years) and the IDH mutation status in POLA cohort.




Figure S2. Progression free-survival (left) and overall survival (right) according to treatment groups in elderly patients with anaplastic oligodendroglioma. RT: radiotherapy; PCV: procarbazine, CCNU, Vincristine; TMZ: temozolomide.